

Albert Lai

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5872339/publications.pdf](https://exaly.com/author-pdf/5872339/publications.pdf)

Version: 2024-02-01

107
papers

4,629
citations

109886

35
h-index

106770

65
g-index

107
all docs

107
docs citations

107
times ranked

6854
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence for Sequenced Molecular Evolution of <i>IDH1</i> Mutant Glioblastoma From a Distinct Cell of Origin. <i>Journal of Clinical Oncology</i> , 2011, 29, 4482-4490.	1.7	420
2	Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2011, 29, 142-148.	1.7	418
3	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. <i>Cell Metabolism</i> , 2015, 22, 508-515.	16.3	190
4	Phase II Pilot Study of Bevacizumab in Combination with Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1372-1380.	0.8	169
5	Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. <i>Lancet Oncology</i> , The, 2022, 23, 53-64.	10.8	165
6	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. <i>Science Translational Medicine</i> , 2016, 8, 341ra75.	12.6	158
7	Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial. <i>Radiology</i> , 2014, 271, 200-210.	7.4	150
8	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. <i>Neuro-Oncology</i> , 2018, 20, 1383-1392.	1.3	135
9	Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas. <i>NeuroImage</i> , 2012, 59, 908-916.	4.3	128
10	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. <i>Neuro-Oncology</i> , 2013, 15, 57-68.	1.3	128
11	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 134, 177-188.	3.0	118
12	Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2. <i>Clinical Cancer Research</i> , 2007, 13, 2592-2598.	7.1	108
13	18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. <i>Neuro-Oncology</i> , 2012, 14, 1079-1089.	1.3	99
14	Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. <i>Neuro-Oncology</i> , 2013, 15, 370-381.	1.3	97
15	pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. <i>Neuro-Oncology</i> , 2015, 17, 1514-1524.	1.3	96
16	Oculodentodigital dysplasia connexin43 mutations result in non-functional connexin hemichannels and gap junctions in C6 glioma cells. <i>Journal of Cell Science</i> , 2006, 119, 532-541.	2.0	91
17	Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. <i>Neuro-Oncology</i> , 2013, 15, 626-634.	1.3	91
18	Patient-Specific Metrics of Invasiveness Reveal Significant Prognostic Benefit of Resection in a Predictable Subset of Gliomas. <i>PLoS ONE</i> , 2014, 9, e99057.	2.5	89

#	ARTICLE	IF	CITATIONS
19	Safety of anticoagulation use and bevacizumab in patients with glioma. <i>Neuro-Oncology</i> , 2008, 10, 355-360.	1.3	85
20	Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. <i>Neuro-Oncology</i> , 2014, 16, 414-420.	1.3	82
21	Large-scale assessment of the gliomasphere model system. <i>Neuro-Oncology</i> , 2016, 18, 1367-1378.	1.3	82
22	Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. <i>Journal of Neuro-Oncology</i> , 2011, 102, 477-484.	3.0	68
23	Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. <i>Neuro-Oncology</i> , 2017, 19, 89-98.	1.3	68
24	Human <i>TERT</i> promoter mutation enables survival advantage from <i>MGMT</i> promoter methylation in <i>IDH1</i> wild-type primary glioblastoma treated by standard chemoradiotherapy. <i>Neuro-Oncology</i> , 2017, 19, now189.	1.3	65
25	The <i>MGMT</i> promoter SNP rs16906252 is a risk factor for <i>MGMT</i> methylation in glioblastoma and is predictive of response to temozolomide. <i>Neuro-Oncology</i> , 2015, 17, 1589-1598.	1.3	57
26	Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. <i>Clinical Cancer Research</i> , 2019, 25, 4993-5001.	7.1	57
27	Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1458-1469.	6.4	56
28	Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. <i>Cancer & Metabolism</i> , 2018, 6, 4.	5.0	55
29	Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. <i>PLoS ONE</i> , 2015, 10, e0141334.	2.5	52
30	Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3T. <i>NMR in Biomedicine</i> , 2016, 29, 1563-1576.	2.9	51
31	Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. <i>Neuro-Oncology</i> , 2014, 16, 815-822.	1.3	49
32	Contrast-enhancing tumor growth dynamics of preoperative, treatment-naïve human glioblastoma. <i>Cancer</i> , 2016, 122, 1718-1727.	4.1	47
33	Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy. <i>iScience</i> , 2020, 23, 101453.	4.1	47
34	Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1195-1203.	0.8	45
35	Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. <i>Molecular Cancer</i> , 2015, 14, 189.	19.4	38
36	Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3T using multi-echo amine proton chemical exchange saturation transfer spin-echo gradient echo echo-planar imaging (CEST-SAGE-EPI). <i>Magnetic Resonance in Medicine</i> , 2018, 80, 1962-1978.	3.0	38

#	ARTICLE	IF	CITATIONS
37	Signal-dependent Trafficking of β -Amyloid Precursor Protein-Transferrin Receptor Chimeras in Madin-Darby Canine Kidney Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 3732-3739.	3.5	35
38	Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 351-358.	3.0	34
39	^{18}F -FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. <i>Journal of Neuro-Oncology</i> , 2018, 139, 399-409.	3.0	32
40	Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. <i>Scientific Reports</i> , 2019, 9, 2846.	3.4	32
41	Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1-Mutant Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 5808-5822.	7.1	30
42	Relationship Between ^{18}F FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. <i>Molecular Imaging and Biology</i> , 2015, 17, 434-442.	2.7	28
43	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. <i>Neuro-Oncology</i> , 2019, 21, 1184-1196.	1.3	28
44	pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 587-595.	3.0	28
45	Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. <i>Clinical Cancer Research</i> , 2015, 21, 4373-4383.	7.1	27
46	Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1229-1237.	3.5	27
47	A gene expression signature predicts recurrence-free survival in meningioma. <i>Oncotarget</i> , 2018, 9, 16087-16098.	1.8	26
48	Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 139, 651-659.	3.0	25
49	Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T. <i>American Journal of Neuroradiology</i> , 2019, 40, 979-986.	2.4	24
50	Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage. <i>Journal of Neuro-Oncology</i> , 2013, 113, 365-373.	3.0	23
51	Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. <i>NeuroImage: Clinical</i> , 2015, 9, 617-624.	2.8	23
52	Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. <i>Scientific Reports</i> , 2020, 10, 11922.	3.4	23
53	Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. <i>Journal of Neuro-Oncology</i> , 2017, 134, 357-362.	3.0	22
54	ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E-MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG). <i>Neuro-Oncology</i> , 2019, 21, vi19-vi20.	1.3	20

#	ARTICLE	IF	CITATIONS
55	Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. <i>CNS Oncology</i> , 2015, 4, 247-256.	3.0	16
56	Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. <i>Neurosurgery</i> , 2020, 87, 931-938.	1.1	14
57	Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. <i>Scientific Reports</i> , 2020, 10, 14819.	3.4	13
58	Voxelwise and Patientwise Correlation of ¹⁸ F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes. <i>Journal of Nuclear Medicine</i> , 2021, 62, 319-325.	5.1	13
59	Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. <i>Cancer Imaging</i> , 2021, 21, 27.	2.8	13
60	The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. <i>Neuro-Oncology</i> , 2009, 11, 22-32.	1.3	12
61	Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. <i>Brain Tumor Pathology</i> , 2018, 35, 1-9.	1.8	12
62	Rate of change in maximum ¹⁸ F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 147, 135-145.	3.0	12
63	Diffusion MRI Characteristics after Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. <i>Tomography</i> , 2015, 1, 37-43.	1.8	12
64	Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1565-1576.	4.1	11
65	PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. <i>PET Clinics</i> , 2013, 8, 201-217.	3.0	8
66	D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced <i>MIR148A</i> Promoter Methylation. <i>Molecular Cancer Research</i> , 2018, 16, 947-960.	3.5	8
67	SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. <i>Journal of Neuro-Oncology</i> , 2019, 142, 423-434.	3.0	8
68	Bevacizumab as First-Line Therapy for Glioblastoma. <i>Future Oncology</i> , 2012, 8, 929-938.	2.4	7
69	Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. <i>Experimental and Molecular Pathology</i> , 2017, 103, 87-93.	2.2	7
70	Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series. <i>CNS Oncology</i> , 2019, 8, CNS35.	3.0	7
71	Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. <i>Neuroradiology</i> , 2021, 63, 857-868.	2.2	7
72	Prognostic value of <i>O</i> 6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas. <i>Neuro-Oncology Advances</i> , 2022, 4, vda030.	0.7	7

#	ARTICLE	IF	CITATIONS
73	Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. <i>Neuro-Oncology</i> , 2014, 16, 1427-1428.	1.3	6
74	FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab017.	0.7	6
75	Tyrosine-dependent basolateral targeting of human connexin43-eYFP in Madin-Darby canine kidney cells can be disrupted by the oculodentodigital dysplasia mutation L90V. <i>FEBS Journal</i> , 2009, 276, 6992-7005.	4.8	5
76	Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 337-346.	3.0	5
77	Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. <i>Journal of Neuro-Oncology</i> , 2020, 147, 643-652.	3.0	5
78	Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1022-1029.	2.2	5
79	Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)., 2021, , .		5
80	Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI). <i>Brain Imaging and Behavior</i> , 2022, 16, 239-251.	2.1	5
81	Contrast-enhanced T1-weighted subtraction maps for response assessment in recurrent glioblastoma treated with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2055-2055.	1.7	4
82	RARE-09. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E-MUTATED HIGH-GRADE GLIOMA (HGG). <i>Neuro-Oncology</i> , 2018, 20, vi238-vi238.	1.3	3
83	Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. <i>Neuro-Oncology Practice</i> , 2019, 6, 103-111.	1.6	3
84	CBMT-31. HDAC INHIBITION DIMINISHES THE GROWTH OF ENDOGENOUS IDH MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi39-vi40.	1.3	2
85	Preferential tumor localization in relation to 18F-FDOPA uptake for lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2021, 152, 573-582.	3.0	2
86	Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life. <i>CNS Oncology</i> , 2022, 11, CNS84.	3.0	2
87	Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study. <i>Cancers</i> , 2022, 14, 2520.	3.8	2
88	NCMP-01. SEIZURE CONTROL AFTER INITIAL PRESENTATION IN IDH MUTATED GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2017, 19, vi135-vi136.	1.3	1
89	Final results of a single-arm phase II study of bevacizumab and temozolomide following radiochemotherapy in newly diagnosed adult glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2076-2076.	1.7	1
90	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease. <i>Frontiers in Oncology</i> , 2022, 12, 849993.	2.9	1

#	ARTICLE	IF	CITATIONS
91	BI-10 * pH-WEIGHTED MRI IN HUMAN GLIOMAS. <i>Neuro-Oncology</i> , 2014, 16, v25-v25.	1.3	0
92	DDIS-10. TARGETING HGF/MET IN GBM BY RESTORING SPINT2 FUNCTION. <i>Neuro-Oncology</i> , 2016, 18, vi49-vi49.	1.3	0
93	NIMG-31. RESIDUAL ENHANCING TUMOR VOLUME IS A STRONG PROGNOSTIC BIOMARKER FOR SURVIVAL IN BOTH NEWLY DIAGNOSED AND RECURRENT GBM REGARDLESS OF THERAPY: EVIDENCE FROM 1,535 PATIENTS IN SINGLE AND MULTICENTER TRIALS. <i>Neuro-Oncology</i> , 2016, 18, vi131-vi131.	1.3	0
94	NIMG-56. PATTERNS FROM DYNAMIC VESSEL SIZE IMAGING OF ARTERIAL AND VENOUS PERFUSION CORRELATES WITH AGGRESSIVENESS AND STRATIFIES 1p19q CO-DELETED FROM NON-CODELETED LOW-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2016, 18, vi136-vi137.	1.3	0
95	GENE-41. EPIGENETIC DOWN-REGULATION OF THE METALLOTHIONEIN FAMILY IN ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2017, 19, vi101-vi101.	1.3	0
96	NIMG-15. DIFFERENTIATION OF IDH1 MUTANT AND WILD TYPE GLIOMAS USING pH- AND OXYGEN-SENSITIVE MOLECULAR MRI. <i>Neuro-Oncology</i> , 2018, 20, vi178-vi179.	1.3	0
97	NIMG-59. VALIDATION OF QUANTITATIVE VESSEL SIZE IMAGING (VSI) IN HUMAN GLIOMAS USING IMAGE-GUIDED STEREOTACTIC BIOPSIES. <i>Neuro-Oncology</i> , 2018, 20, vi189-vi189.	1.3	0
98	ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN COMBINATION WITH STANDARD THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN. <i>Neuro-Oncology</i> , 2018, 20, vi13-vi13.	1.3	0
99	NIMG-54. DIFFUSION MRI PHENOTYPES PREDICT OVERALL SURVIVAL BENEFIT FROM BEVACIZUMAB IN RECURRENT GLIOBLASTOMA WITH A LARGE TUMOR BURDEN: EVIDENCE FROM CLINICAL PRACTICE AND A MULTICENTER PHASE 3 TRIAL. <i>Neuro-Oncology</i> , 2019, 21, vi173-vi173.	1.3	0
100	QOLP-12. EVALUATION OF THE UCLA NEURO-ONCOLOGY PROGRAM PSYCHOSOCIAL PATIENT SCREENING FORM IN IDENTIFYING DEPRESSION, FATIGUE, AND PERCEIVED COGNITIVE FUNCTION IN PATIENTS WITH GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi200-vi200.	1.3	0
101	NIMG-60. IDH MUTANT GLIOMAS WITH 1p/19q CO-DELETION ARE LESS ACIDIC THAN NON-CO-DELETED GLIOMAS AS MEASURED WITH PH-WEIGHTED AMINE CEST-MRI AND AMINO ACID PET. <i>Neuro-Oncology</i> , 2019, 21, vi174-vi175.	1.3	0
102	GENE-38. IDH1MUT INDUCES N6-METHYLADENOSINE (m6A) RNA HYPERMETHYLATION VIA D-2-HG IN GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi105-vi106.	1.3	0
103	NIMG-31. BRAIN CONNECTIVITY PATTERNS CHARACTERIZE COGNITIVE IMPAIRMENT IN LONG-TERM SURVIVORS OF LOW-GRADE GLIOMA (LGG) USING RESTING-STATE FUNCTIONAL MRI (rs-fMRI). <i>Neuro-Oncology</i> , 2019, 21, vi167-vi168.	1.3	0
104	NCOG-10. RELATIONSHIP BETWEEN COGNITIVE FUNCTION, MOOD, AND FUNCTIONING IN GLIOMA SURVIVORS. <i>Neuro-Oncology</i> , 2019, 21, vi160-vi161.	1.3	0
105	Patient-specific biomathematical model to predict benefit of resection in human gliomas.. <i>Journal of Clinical Oncology</i> , 2013, 31, e13017-e13017.	1.7	0
106	Characterizing malignant transformation in patients with IDH mutant glioma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2065-2065.	1.7	0
107	A single-institution, retrospective examination of new contrast enhancement, progression, and pseudoprogression in IDH mutant glioma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2043-2043.	1.7	0